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Abstract
Hypertrophic scars (HTS) are characterized by excessive amount of collagen deposition
and principally occur following burn injuries or surgeries. In absence of effective treatments,
the use of mesenchymal stem/stromal cells, which have been shown to attenuate fibrosis in
various applications, seems of interest. The objectives of the present study were therefore
to evaluate the effect of human adipose tissue-derived mesenchymal stem cells (hASC) on
a pre-existing HTS in a humanized skin graft model in Nude mice and to compare the effi-
cacy of hASCs versus stromal vascular fraction (SVF). We found that injection of SVF or
hASCs resulted in an attenuation of HTS as noticed after clinical evaluation of skin thick-
ness, which was associated with lower total collagen contents in the skins of treated mice
and a reduced dermis thickness after histological analysis. Although both SVF and hASCs
were able to significantly reduce the clinical and histological parameters of HTS, hASCs
appeared to be more efficient than SVF. The therapeutic effect of hASCs was attributed to
higher expression of TGFβ3 and HGF, which are important anti-fibrotic mediators, and to
higher levels of MMP-2 and MMP-2/TIMP-2 ratio, which reflect the remodelling activity
responsible for fibrosis resorption. These results demonstrated the therapeutic potential of
hASCs for clinical applications of hypertrophic scarring.
Introduction
Skin wound healing is a biological process that restores the epidermal and dermal layers of the
skin after injuries through successive phases of inflammation, proliferation and remodeling.
Abnormal healing occurs when this process is impaired resulting in chronic wounds or when it
loses control ending with fibrosis or hypertrophy. Hypertrophic scars (HTS) are consequences
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of excessive extracellular matrix (ECM) deposition by fibroblasts and myofibroblasts and infil-
tration of immune cells releasing inflammatory mediators [1]. This excess of ECM occurs
when the inflammatory phase is prolonged and myofibroblasts generate the scarring tissue fill-
ing the defect. Besides its undesirable visual appearance, the scar tissue presents poor mechani-
cal strength relative to the surrounding tissue. HTS are the most common complications that
may develop following burn injury and surgical incisions, and represent an important public
health problem primarily in children and young people [2]. HTS is characteristic of human
skin and does not develop in other animals, although mechanical load may initiate HTS in
mice [3]. While there are several animal models of skin fibrosis (for review, see [4]), a small
number of studies reports the use of models of HTS based on human skin [5]. One of these
studies reports that transplantation of full-thickness human skin grafts leads to HTS three
months after transplantation in an immunocompromised mouse [6]. Indeed, the availability of
such pre-clinical models of HTS represents useful tools to address the effects of treatments.
Current treatments to promote wound healing without scar formation primarily consist in
standard procedures for wound management to attenuate excessive scarring. Many of these
treatments have proven some efficacy and emerging therapies are evaluating the use of recom-
binant TGFβ3 or anti-TGFβ1 antibodies [2]. However, an alternative to these pharmaceutical
treatments could be the application of multipotent mesenchymal stem or stromal cells (MSCs).
MSCs are native constituents of the wound bed [7] but are mainly isolated from bone marrow
(BM), umbilical cord or adipose tissue. They are characterized by their capacity to adhere to
plastic, their phenotype and trilineage differentiation potential [8]. MSCs exert numerous func-
tions through their migratory, anti-inflammatory and trophic properties that may be of interest
for restoring skin tissue function and enhance healing. By secreting anti-inflammatory media-
tors, MSCs influence the inflammatory phase of healing; they are also involved in bacterial
clearance and the stimulation of proliferation and migration of predominant skin cell types [9].
Most of the pre-clinical and clinical studies have evaluated the interest of MSC in the treatment
of acute or chronic non healing wounds [10]. However to our knowledge, there is only one
report on the interest of using bone marrow-derived human MSCs to prevent HTS in the rabbit
model of ear scar [11].
We therefore set up the conditions for HTS formation after the implantation of full thick-
ness human skin grafts onto the back of immunocompromised Nude mice as a relevant model
for evaluating the therapeutic potential of human adipose tissue-derived MSCs (hASCs) on
HTS. We specifically aimed at evaluating the efficacy of ASC injection on the attenuation of a
pre-existing HTS and comparing the local application of hASCs with that of stromal vascular
fraction (SVF).
Methods
Isolation and characterization of adipose tissue-derived mesenchymal
stem cells
Human fat tissue samples were obtained through abdominal dermolipectomy from patients
undergoing plastic surgery after written informed consent signed by the patients. The study
was specifically approved by the French Ministry of Research and Innovation and the Personal
data Protection ethics Committee (CPP) of Languedoc-Roussillon (approval AC-2010-1200).
In accordance with French law on the protection of personal data, the medical records were
anonymized prior to use. Subcutaneous abdominal fat was digested with 250 U/mL of collage-
nase type II at 37°C for 1h. After centrifugation (300 g, 10 min), the stromal vascular fraction
(SVF) was collected, filtered successively through a 100 μm, 70 μm and 40 μm porous filter
(Cell Strainer, BD Biosciences, le Pont-de-Claix, France). Quantification of viable cells was
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performed using a hemocytometer after Trypan blue staining and frozen in liquid nitrogen.
Freshly thawed SVF was immunophenotyped and immediately used for animal
experimentation.
For ASC isolation, SVF prepared freshly as described above was plated at 4000 cells/cm2 in
α-MEMmedium supplemented with 100 U/mL penicillin/streptomycin, 2 mmol/mL gluta-
mine and 10% fetal calf serum. After one week in culture (end of passage 0), adherent fibroblas-
tic hASCs were characterized by their immunophenotype (positive for CD13, CD73, CD90,
CD105 and negative for CD14, CD31, CD34, CD45) (S1 Fig), their trilineage potential of dif-
ferentiation as published [12] and frozen. For the experiments, hASCs were thawed, expanded
in culture for 1 week and used before 14 population doublings (end of passage 1).
Flow cytometry analysis
SVF (100 μL) or hASCs (1×105) in PBS containing 0.2% bovine serum albumin (BSA) were
incubated with 1 μL of antibodies for 20 min at 4°C in the dark. Antibodies tested were: CD13,
CD14, CD31, CD34, CD45, CD73, CD90 or CD105 antibodies or the respective isotype con-
trols (BD-Biosciences). The labeled cells were then analyzed by multiparameter flow cytometry
using a FACSCanto cytometer and the Diva software (BD-Bioscience).
Skin samples
Full thickness skin (1.5 mm in thickness), which corresponded to the epidermis and dermis
layers, without the underlying hypodermis, was obtained from healthy women undergoing
mammary reduction after informed consent and approval by the Local Ethical Committee
(registration number: LB-2012-12-01). Skins were wrapped with saline soaked gauze and
placed in a sterilized instrumental box at room temperature for transport to the neighboring
laboratory. Skins were grafted between 30 min to 6 hours after removal.
Animal experimentation
Athymic Nude-Foxn1numice aged 6–7 weeks were obtained from Harlan (Gannat, France)
and housed at the animal facility in controlled conditions. Animal experimentation was con-
ducted in agreement with the Languedoc-Roussillon Regional Ethics Committee on Animal
Experimentation (approval CEEA-LR-11053). All surgery was performed under isoflurane gas
anesthesia, and all efforts were made to minimize suffering and to reduce animal numbers.
Animals received oral paracetamol for the first few days after graft and were monitored weekly
for graft outcomes.
Skin samples from two donors were used: half of the mice were implanted with the skin of
one donor and half with the skin of the other donor. Because in preliminary experiments we
found out that approximately 25% of skin grafts did not succeed (essentially because only part
of the graft survived), 40 mice were implanted. A circular piece of skin (2 cm in diameter) was
removed on the back of mice. Human skin samples (2 cm in diameter and 1.5 mm in thickness)
were grafted to fit into the prepared graft sites and fixed in position with 5.0 suture (Optim' R1
5.0; Peters Surgical, Bobiny, France) and suture dressing (Urgotul1; Urgo Laboratory, Che-
nove, France). An extensive bandage was applied during 10 days after grafting to prevent graft
desiccation. Clinical follow-up was performed every week for 9 weeks after grafting. Measure
of skin graft thickness was performed once a week using a caliper by the measurement tech-
nique of skinfold. Briefly, the graft skin and the neighboring mouse skin were pinched between
two fingers in order to overlay both skins. Measure of the graft thickness took into account
both the human and mouse skins. The mouse skin thickness being low and similar between
mice, most of the differences were accounted for the human grafts.
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At week 7 after implantation, 30 mice were selected after visual examination of the grafts
and mice were separated in 3 groups of 10 mice with homogeneous skin grafts. Grafts were
treated with phosphate buffered saline (PBS), hASCs or SVF. The day of injection, the quantity
of hASCs contained in a freshly thawed SVF was determined by flow cytometry. Cells positive
for CD13, CD34, CD73, CD90 and negative for CD14, CD31, CD45 were considered hASCs
and accounted for 45% of the cells in the SVF. SVF containing 106 hASCs (100 μL) was injected
subcutaneously in the scar in the 4 cardinal points in one group (n = 10). A total of 106 cultured
hASCs in 100 μL was injected in the second group (n = 10) and 100 μL of PBS was injected into
the control group (n = 10). At week 8, 5 mice/group were euthanatized and the remaining 5
mice/group were euthanatized at week 9. Euthanasia was performed by CO2 inhalation. The
day of sacrifice, scar thickness was measured with a caliper. Skin graft punches (6 mm in diam-
eter) were recovered and either frozen at -80°C for RNA and collagen analysis or fixed in 3.7%
formaldehyde for histology.
Histological analysis
Skin samples were embedded in paraffin and cut in sections of 5 μm, stained with Masson’s
Trichrome for analysis of collagen-rich and fibrotic areas. Histological sections were scanned
using a nanozoomer digital slide scanner (Hamamatsu, Massy, France). Mean skin thickness
was calculated on more than 30 points from each section using ImageJ skin tool plugin. Results
are expressed in μm. Fibrosis and scar were quantified on skin sections as follows: demarcation
between papillary and reticular layers was scored 1 when it could not be evaluated and 0 when
clearly preserved; presence of dense collagen fibers and disorganization in collagen bundles
was scored 1 or 0 when absent or normally organized; disorganization in elastic fibers including
fragmented, agglutinated fibers was scored 1 or 0 for normal appearance. In addition, fibrosis
was scored as follows: 0 for no fibrosis, 1 for thin fibrosis that did not concern all dermis, 2 for
dense thick hyaline fibrosis. A scar score (from 0 to 7) was established based on these parame-
ters and used to compare skin sections between groups.
Sections of paraffin-embedded samples were immunostained with antibodies for human
pan-cytokeratin, cytokeratin 5/6, involucrin or α-Sma (Abcam, Paris) or stained for DAPI.
Collagen content in skin
Collagen content assay was based on the quantitative dye-binding Sircol method (Biocolor,
Interchim, Montluçon, France). Skin biopsies were suspended in 2 mL of a 0.5 M acetic acid/
pepsin solution and dissociated with a dispenser tool (Ultra-Turrax IKA, VWR, Fontenay-
sous-Bois). Collagen extraction was performed at 4°C overnight under stirring. The suspension
was then centrifuged at 12,000 g for 10 min. Part of the supernatant (20 μL) was used for total
protein quantification using the BCA assay (Sigma) and another part (20 μL) of the sample was
added to 1 mL of Syrius red reagent. After 30 min agitation at room temperature, samples were
centrifuged at 12,000 g for 10 min and supernatants discarded. Pellets were washed with
750 μL of ice-cold salt acid and centrifuged at 12,000 g for 10 min, before resuspension in 1 mL
of 0.5 M NaOH Alkali solution. Optical density was then read at 555 nm on a microplate reader
(Varioskan Flash, Thermo Scientific, Courtaboeuf, France) versus a standard range of bovine
collagen type I concentrations (supplied as a sterile solution in 0.5 M acetic acid). Results were
expressed in mg of collagens/mg of total proteins.
RNA extraction and real time RT-PCR
Skin punches were mechanically dissociated using a dispenser tool (Ultra-Turrax IKA, Imlab,
Lille, France). Punches were suspended in lysis buffer for dissociation and RNA extraction was
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performed using the RNeasy mini kit and Qiacube robotic workstation as recommended by the
supplier (Qiagen, Courtaboeuf, France). Quality and quantity of RNA were checked on a
NanoDrop spectrophotometer (Thermo Scientific, Villebon sur Yvette, France). One μg RNA
was reverse transcribed using 100 units of the Moloney Murine Leukemia Virus Reverse Tran-
scriptase (M-MLV RT, Invitrogen). Reverse Transcription conditions were as follow: 25°C for
10 min; 37°C for 50 min and 70°C for 15 min. Real time PCR (qPCR) was performed on 20ng
RNA in 10μL that contained 5μl of DNAMaster SYBR Green I kit (Roche Diagnostics, Mey-
lan) and 0.05μM primers. Sequences of primers were designed using the web-based applica-
tions Primer3 and BLAST and reported in Table 1 (). The following PCR conditions were used:
95°C for 5min; 40 cycles at 95°C for 15s; 64°C for 10s and 72°C for 20s in a LightCycler 480 sys-
tem (Roche diagnostics, Meylan, France) and analyzed with the dedicated software. Results
were provided as relative expression to the housekeeping gene tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta (YWHAZ) using the formula 2−ΔCt.
Statistical analysis
Statistical analysis was performed with GraphPad Software (San Diego, CA). Comparison
between groups used Shapiro-Wilk normality test. Data were compared using the Mann-Whit-
ney’s test for nonparametric values. A p value 0.05 was considered significant.
Results
Full-thickness human skin graft induced hypertrophic scar formation in
Nude mice
We first aimed at setting up the conditions for hypertrophic scar formation after implantation
of human skin grafts onto the back of immunodeficient mice in which a piece of skin of
Table 1. List of primers used in RT-qPCR experiments.
Gene abbreviation Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’)
aSma CATCGGGATGGAGTCTGCTG AGAAGCATTTGCGGTGGACA
Col1 CCTGGATGCCATCAAAGTCT CGCCATACTCGAACTGGAAT
Col3 CGCCCTCCTAATGGTCAAGG AGGGCCTGAAGGACCAGCTT
Hgf CCCCATCGCCATCCCCTATG ACATCTATTAGCACATTGGTCTGCACT
IFNγ ATGTCCAACGCAAAGCAATACATGAAC ACCTCGAAACAGCATCTGACTCCT
IL6 TTCTCCACAAGCGCCTTCGGTC GAATCTTCTCCTGGGGGTACTGGGG
Mmp1 AGGCCCAGGTATTGGAGGGGA GCCGATGGGCTGGACAGGATT
Mmp2 GCCGTCGCCCATCATCAAGTT ATAGAAGGTGTTCAGGTATTGCACTG
Mmp3 TTGCGCCAAAAGTGCCTGTCT GGAGCCAGGCTTTCCCAAGCA
Mmp9 CAAGGGCGTCGTGGTTCCAA GGCCCTCGAAGATGAAGGGGAAGT
Mmp13 TAAGGAGCATGGCGACTTCT GTCTGGCGTTTTTGGATGTT
Tgfb1 ACTGCAAGTGGACATCAACGGGTTCAC GCCATGAGAAGCAGGAAAGGCCGGT
Tgfb3 CTAAGCGGAATGAGCAGAGGATC TCTCAACAGCCACTCACGCACA
Timp2 AGGGCCAAAGCGGTCAGTGA AACGTCCAGCGAGACCCCAC
Tnfa AGCCCATGTTGTAGCAAACCCTC TGGTTATCTCTCAGCTCCACGCCA
VegfA CTTGCTGCTCTACCTCCACC ATGATTCTGCCCTCCTCCTT
Ywhaz AGTTAAGGGCCAGACCCAGT AGACGGAAGGTGCTGAGAAA
aSma: α-smooth muscle actin; Col: collagen; Hgf: hepatocyte growth factor; Ifnγ: interferon γ; IL6: Interleukin 6; Mmp: matrix metalloproteinase; Tgfb:
transforming growth factor β; Timp: tissue inhibitor of metalloproteinase; Tnfa: Tumor necrosis factor α; Vegf: vascular endothelial growth factor; Ywhaz:
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
doi:10.1371/journal.pone.0156161.t001
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comparable diameter has been removed. We therefore tested the implantation of human full-
thickness skin grafts that were sutured to the mouse skin (Fig 1A). Two weeks after grafting,
the superficial layer of the graft was not viable as indicated by white, thick and retractile over-
laying tissue. Grafts then became brown and black before necrosis falling down slowly. When
necrotic areas appeared in the central zone, a raised bead formed in the peripheral zone around
week 5 (Fig 1A). Healing then progressed from the periphery to the central zone while a raised
scar developed.
During these healing phases, we measured the skin thickness from week 6 to week 9, when
the necrotic zone has disappeared. Compared to the thickness of skin at implantation (day 0), a
high and significant increase of skin thickness was observed at week 6, that plateaued at week 7
and 8 (Fig 1B). Although still higher than normal skin (week 0), skin thickness was however
significantly reduced at week 9 as compared to week 7, indicating a spontaneous resorption of
hypertrophy. Monitoring the collagen content in skin biopsies recovered at week 8 and 9 con-
firmed that fibrosis with high collagen deposits occurred in the grafts with time (Fig 1C). In
concordance with skin thickness decrease, a significant reduction of collagen content was
observed in skins biopsied at week 9 as compared to week 8.
Histological analyses of skin biopsies performed at week 9 compared to normal skin indi-
cated thickening of the epidermis and dermis layers. The most striking effect was observed in
the epidermal layer, which was thicker in HTS skins than in control skins (Fig 2A, upper pan-
els). In HTS samples, dermis was disorganized (Fig 2A, lower panels). The demarcation
between the papillary and reticular layers of dermis was imprecise. In the dermis, a scar tissue
Fig 1. Human skin grafts in a humanized mousemodel. (A) Macroscopic images of two examples of
human skins (up and down panels) grafted onto the back of two immunocompromised Nude mice at different
time points. (B) Measures of human skin graft thickness at different time points. (C) Quantification of collagen
content in skin grafts at euthanasia. Results are expressed as the mean ± SEM (standard deviation of the
mean), n = 5/group. *p<0.05, **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0156161.g001
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with thick hyaline fibrosis was observed. Collagen fibers were dense, with disorganization in
collagen bundles. Elastic fibers appeared spaced and fragmented.
Further characterization of skin grafts aimed at evaluating the presence of human tissue at
the site of implantation. Using antibodies specific for human epidermis, we observed high
staining for pan-keratin throughout the epidermal layer in the human skin while such high
Fig 2. Hypertrophic scar formation in a humanized mousemodel. (A) Masson’s trichrome staining of control human skin
grafts (Ctrl; left) or hypertrophic scar (HTS; right) at week 8. Pictures focused on epidermis (upper panels) and dermis (lower
panels) at samemagnification (scale bar is 100 μm). (B) Immunohistochemical staining of HTS skins using antibodies specific
for human pan-cytokeratin (upper left panel), human cytokeratin 5/6 (lower left panel), human involucrin (upper right panel)
(scale bar is 250 μm). Immunofluorescence using an antibody specific for α-Sma (lower right panel) (magnification x40).
Arrow indicated the demarcation between human (left) and mouse (right) tissues.
doi:10.1371/journal.pone.0156161.g002
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staining was not observed in the neighboring murine epidermis (Fig 2B, upper left panel; see
the arrow indicating the demarcation between human (left) and murine (right) tissues). High
staining for cytokeratin 5/6 was localized in the basal layer of human but not of murine epider-
mis (Fig 2B, lower left panel) while involucrin was expressed uniquely in human epidermis but
at low levels (Fig 2B, upper right panel). Finally, fibrosis was characterized by high expression
of α-Sma in the dermis of human HTS skins (Fig 2B, lower right panel) while scarce staining
was observed in murine skin (data not shown).
Because skin thickness was maximal at week 8 after graft implantation and decreased at
week 9, we evaluated the expression levels of markers characteristic of fibrotic scar at these two
time points. The expression of transcripts for collagen type I and III were highly upregulated at
weeks 8 and 9 as compared to day 0 (time of skin implantation) while α-Sma was significantly
reduced at both time points (Fig 3). Expression of TGF-β1 was significantly increased by week
8 and reduced by week 9. Similar expression profiles were observed with the marker of angio-
genesis VEGF and markers of remodeling MMP-3, MMP-9. Although TIMP-2 expression
tended to decrease at both time points, the decrease was not significant. Altogether clinical, his-
tological and molecular parameters indicated that human full-thickness skin grafts formed a
hypertrophic scar between 6 and 8 weeks after implantation in Nude mice.
Injections of SVF or hASCs improved hypertrophic scarring
Using this model of hypertrophic scarring, we investigated whether hASCs could reduce hyper-
trophic fibrosis and compared the effect of hASCs with that of SVF. We used freshly thawed
SVF and culture expanded hASCs. The day of injection, SVF preparations were immunophe-
notyped to determine the percentage of hASCs in the samples (S1 Fig). We injected a similar
quantity of hASCs (either cultured hASCs or hASCs in the SVF suspension) in the grafts.
Based on the kinetics of hypertrophic scarring, we decided to inject the cell suspensions at
week 7 and to monitor different parameters 1 and 2 weeks later. At the macroscopic level, no
clear difference was observed between treated and control groups at week 8 (Fig 4A). At week 9
however, scars became flatter after SVF or hASC treatment than in the control group. This was
confirmed by the measure of skin thickness. One week after injection (week 8), the skin thick-
ness tended to be lower in the treated groups as compared to the control group but with no sig-
nificant difference. By contrast at week 9, a significant decrease of the skin thickness was
measured in both SVF- and hASC-treated groups (Fig 4B). The reduction of skin thickness was
even more significant in hASC-treated group than in SVF-treated group as compared to con-
trol. Similar results were observed with the quantification of the collagen content in the skins at
euthanasia. While there was no difference in collagen content between groups at week 8, both
treated groups displayed lower amounts of collagens than HTS skins at week 9 (Fig 4C). The
difference was even more significant in the hASC-treated group than in the SVF-treated group.
At the histologic level, the thickness of both epidermis and dermis were decreased in hASC-
and SVF-treated groups compared to control at week 8 and 9 (Fig 5A and 5B, upper panels).
This was reflected by the quantification of epidermis and dermis thickness on histological sec-
tions. A tendency to lower epidermis thickness was observed in SVF and hASC-treated groups
at week 8, although differences between groups were not significant (Fig 5C). Nevertheless, der-
mis thickness was significantly lower in hASC-treated skin sections at weeks 8 as compared to
control and tended to be still lower at week 9 (Fig 5C). Collagen fibers, which were disorga-
nized in control groups, appeared less dense and organized in parallel bundles of fibers in the
hASC-treated group (Fig 5A and 5B, lower panels). Scar score, as defined in Materials and Sec-
tions, confirmed significant reduction of fibrosis in skin sections of hASC-treated skins as com-
pared to control mice at week 8, but not at week 9 (Fig 5D).
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SVF or hASC injections enhanced fibrosis remodeling
In order to determine by which mechanisms hASCs or SVF might influence the decrease in
skin fibrosis, we performed transcriptomic analysis of several genes involved in fibrosis, vascu-
larization, tissue remodeling or inflammation. At week 8, we observed no significant variations
of transcript levels for the fibrotic markers collagen type I, collagen type III or α-Sma between
hASC- or SVF-treated groups and control HTS groups (Fig 6A). We however detected a
Fig 3. Expression of fibrotic and remodellingmarkers in the hypertrophic scar humanized mouse
model.Measure of mRNAs of the indicated genes normalized to human YWHAZ expression in skin samples
at weeks 8 and 9. Results are expressed as the mean ± SEM (standard deviation of the mean), n = 5/group.
*p<0.05, **p<0.01.
doi:10.1371/journal.pone.0156161.g003
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significant reduction of TGF-β1 expression in SVF-treated mice and of VEGF expression both
in hASC- and SVF-treated groups. By contrast, the expression of TGF-β3 significantly
increased in hASC-treated mice. Looking at markers involved in matrix remodeling, we did
not detect any significant changes in the expression of MMP-1, -3, -9 and -13 between groups.
However, we measured significantly increased expression levels of MMP-2 and the ratio
Fig 4. Reduction of hypertrophic scar after SVF or hASC injection in the hypertrophic scar humanized
mousemodel. (A) Macroscopic images of human hypertrophic scar (HTS) grafted onto the back of
immunocompromized Nude mice at week 7 (w7) at the time of cell injection (upper panels). Same HTS after
injection of saline (Ctrl, left), SVF (middle) or hASCs (right) at weeks 8 and 9. (B) Measures of human skin
graft thickness at different time points after saline, SVF or hASC injection. (C) Quantification of collagen
content in skin grafts after saline, SVF or hASC injection and measured at euthanasia (weeks 8 or 9). Results
are expressed as the mean ± SEM (standard deviation of the mean), n = 5/group. *p<0.05, **p<0.01.
doi:10.1371/journal.pone.0156161.g004
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MMP-2/TIMP-2 in hASC-treated group versus control group. Concerning inflammatory fac-
tors, no changes were detected between groups. Interestingly HGF, which is a well-known
Fig 5. Histological evaluation of hypertrophic scar after SVF or hASC injection in the hypertrophic
scar humanized mousemodel. (A) Masson’s trichrome staining of control hypertrophic scars injected with
saline (HTS; left), SVF (middle) or hASCs (right) at weeks 8 (scale bar is 1 mm in upper panels and 100 μm in
lower panels). (B) Same as in A) at week 9. (C) Quantification of epidermis and dermis thickness on
histological sections of the grafts after saline, SVF or hASC injection and measured at euthanasia (weeks 8
or 9). (D) Fibrotic score evaluated on histological sections of groups described in C). Results are expressed
as the mean ± SEM (standard deviation of the mean). n = 5/group (one experiment representative of two).
*p<0.05.
doi:10.1371/journal.pone.0156161.g005
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negative regulator of inflammatory and fibrotic markers, was highly up-regulated in hASC-
treated group. At week 9, the expression levels of these different markers were similar in all the
groups except for MMP-1, which was significantly increased after hASC treatment (S2 Fig).
Finally, we looked at the expression of α-Sma at the protein level in the skins of control and
treated groups. While several zones stained highly positive for α-Sma in the dermis of HTS
skins, rare zones of α-Sma positive staining was observed in the skins of hASC- or SVF-treated
skins (Fig 6B). Therefore, the efficacy of SVF and hASCs to reduce HTS at the clinical and his-
tological level was likely related to their anti-fibrotic effect as indicated by expression of anti-
fibrotic and remodeling markers.
Fig 6. Expression of fibrotic, remodelling and inflammatory markers after SVF or hASC injection in
the hypertrophic scar humanized mousemodel. (A) Measure of mRNAs of the indicated genes
normalized to human YWHAZ expression in skin samples at week 8. Results are expressed as the
mean ± SEM (standard deviation of the mean). n = 5/group. *p<0.05, **p<0.01. (B) Representative pictures
of α-Sma positive areas in skin grafts after saline, SVF or hASC injection at week 8 by immunofluorescence
staining.
doi:10.1371/journal.pone.0156161.g006
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Discussion
In the current study, we demonstrated that the local application of human SVF or hASCs effi-
ciently reduced skin fibrosis in a relevant model of human HTS, as shown by reduced skin
thickness, lower collagen content and regulated expression of fibrotic and remodelling
mediators.
We here described a humanized model of HTS following the transplantation of full-thick-
ness human skin grafts recovered following macromastia surgery. A similar model of full thick-
ness skin graft has been described some years ago [6]. In this last study, HTS developed at 3
months, reaching a peak in thickness by months 5–6 and then decreasing at month 8. The
explanation for the shorter delay observed in our study is not known although it could be
attributed to the site of skin sampling, age of the patients or skin thickness. In our conditions,
HTS was maximal at weeks 6–8 and decreased thereafter. Spontaneous and partial regression
of hypertrophic scars is also observed in humans over time and this characteristic distinguishes
HTS from keloids [13]. In preliminary experiments, we used split thickness skin grafts and we
observed a good healing of the grafts but no hypertrophic scar formation (data not shown) con-
firming that full-thickness skin grafts are required.
Previous results have described that BM-derived MSCs can prevent the formation of HTS in
a rabbit model of ear scarring. In one study, the local application of human BM-MSCs reduced
the thickness of granulation tissues at day 14 post-lesion and prevented scar formation [11].
The observed effects were associated with reduced inflammation mediated by secretion of
TSG-6 by MSCs, which were activated by the pro-apoptotic environment. TSG-6 was shown to
decrease MCP-1, MIP-1α, IL-6 and TGF-β1, inducers of inflammation and fibrosis. TSG-6
secretion was induced in pro-apoptotic caspase-3-positive MSCs. In another study, the same
authors reported similar results using systemic infusion of rabbit BM-MSCs [14]. The anti-
scarring function of MSCs was p53-dependent and related to the inhibition of both myofibro-
blast differentiation and NO production. Our results are in line with these two studies and pro-
vide further information. First, we relied on the use of a humanized model, which reproduces
the main characteristics of human HTS: skin fibrosis, high collagen deposition, increased levels
of fibrotic, remodelling markers as well as spontaneous but slow resorption of the scar [2]. We
could not investigate the anti-inflammatory function of hASCs on cells of the adaptive immu-
nity since we used immunodeficient mice. Of interest, this pre-clinical model allowed evaluat-
ing the therapeutic potential of human ASCs on human skin grafts, which is closer to the
clinical situation. Second, we were able to show that fat-derived SVF or hASC injection can effi-
ciently reduce a pre-existing HTS, which as far as we know, has not been previously investi-
gated. Although the interest of SVF or hASCs has been investigated for wound healing, no data
on their effect on HTS is available.
The use of SVF transplantation has been tested for soft tissue repair, for breast or face recon-
struction [15]. It has also been evaluated to treat patients with radiation-induced severe burns
where a systematic improvement and even remission of clinical and histological symptoms
were observed in these untreatable irradiated patients [16]. More recently, autologous SVF
injection in 12 patients with systemic sclerosis resulted in a significant improvement in hand
disability and pain, Raynaud's phenomenon, finger oedema and quality of life [17]. The hASCs
in the SVF were proposed to be the major mediators of the therapeutic effect and culture
expanded hASCs are being evaluated in clinical trials [18, 19]. The interest of hASCs has been
demonstrated ex vivo and in vivo in murine models of wound healing when injected into the
wound or applied within a scaffold [20–22]. hASC application reduced the wound size and
accelerated re-epithelialization at the wound edge. Additionally, hASC-enriched fat grafts
implantation in patients for reconstructive surgery improved the survival of grafts as compared
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to control fat grafts [23]. On the 13 patients enrolled, those receiving hASC-enriched fat had
significantly higher skin residual volumes as compared to control grafts, with no serious
adverse effects. Here we provide evidence that both SVF and hASCs accelerated healing of
HTS; the therapeutic effect being however more significant with hASCs than SVF. Such com-
parative studies on the therapeutic potential of SVF versus hASC are scarce and to our knowl-
edge, not performed for skin healing. In a recent study, intraperitoneal administration of SVF
was compared with hASC or BM-derived MSC in a murine model of autoimmune encephalo-
myelitis [24]. All cell preparations significantly ameliorated the clinical signs of the disease and
the SVF cells were as effective as culture expanded cells in their ability to reduce disease pro-
gression. In this last study however, the quantity of hASCs and of total SVF was identical.
Here, we injected the same quantity of hASCs (106 cultured hASCs or SVF cells containing 106
hASCs) and observed a better effect with isolated hASCs. This suggested that culture expanded
hASCs have a high capacity to reduce the clinical symptoms of HTS and that other cell subsets
present in the SVF could partly interfere with the function of hASCs A recent study demon-
strated that even modest adipose tissue expansion was characterized by a strong state of T lym-
phocyte activation. T lymphocyte activation was correlated with anti-inflammatory cytokine
production likely associated with the presence of T regulatory cells [25]. The non-ASC cell
components of the SVF could therefore play a role in modulating the function of hASCs.
The mechanisms by which hASCs may decrease fibrosis have been partly documented [26,
27]. Through the secretion of HGF or adrenomodullin, hASCs can reduce the expression of
TGFβ1 and its target genes such as collagen type I, type III and α-Sma. Although only signifi-
cant for TGF-β1,we observed the down-regulation of all these genes at day 8 after SVF injec-
tion, but not after hASC injection. However, hASCs induced a highly significant increase of
TGFβ3 expression, resulting in a change in the TGFβ1/TGFβ3 ratio in favour of an anti-fibrotic
effect. By contrast, hASCs tended to up-regulate MMP-1, -3 and significantly up-regulated
MMP-2 and MMP-2/TIMP-2 ratio, while SVF cells did not. These results might suggest that
cultured hASCs acted more likely on the remodelling of the fibrotic extracellular matrix while
SVF cells regulated the TGFβ1 pathway. However, the uncoupling of these processes was
unlikely. Another possible explanation might be a fast-acting effect of cultured hASCs upon
injection, which was not detectable at the level of mRNAs 1 week after implantation. This was
further supported by equivalent expression levels for the different genes, two weeks after
implantation where the differences in skin thickness between the three groups of mice were the
highest. Another possible mode of action could be through the modulation of miRNAs by
hASCs. Such miRNAs, in particular miR-29a, has been reported to be decreased in bleomycin-
induced fibrosis mouse model [28]. The possibility that hASCs could add by up-regulating
miR-29a, which targets collagens and TIMPs, could not be excluded. Both SVF cells and
hASCs have also been shown to exert an anti-apoptotic effect on the skin tissue [11, 29] The
global effect of hASCs on healing was likely due to a balance between different modes of action,
that still need to be further investigated.
Altogether, our results demonstrated the therapeutic efficacy of hASCs in a humanized
model of HTS. Interestingly, both culture expanded hASCs and SVF cells exerted a similar
anti-fibrotic effect on a pre-existing fibrous tissue, even though isolated hASCs seemed to
reduce more efficiently the fibrotic scar. This study highlighted the therapeutic potential of
hASCs for clinical applications of hypertrophic scarring.
Supporting Information
S1 Fig. Characterization of the SVF and hASCs by immunophenotyping. (A) Representative
histograms of SVF immunophenotype as determined by multicolour staining and FACS
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analysis. Live cells in the freshly thawed SVF were gated according to the expression of CD45
antigen. Among the CD45- cells, CD31+CD34+ endothelial cells and CD31-CD34+ hASCs were
detected, while the CD45+ cells contained CD14+ macrophages and CD14- lymphocytes. (B)
Percentage of cells positive for the indicated markers in the CD45-CD31-CD34+ hASC popula-
tion. (C) Average percentage of the different immune cell subsets in the SVF as shown in A).
(D) Percentage of cells positive for the indicated CD markers in the ASC population obtained
after expansion for 1 week in culture (end of P0).
(JPG)
S2 Fig. Expression of fibrotic, remodelling and inflammatory markers after SVF or ASC
injection in the hypertrophic scar humanized mouse model.Measure of mRNAs of the indi-
cated genes normalized to human YWHAZ expression in skin samples at week 9. Results are
expressed as the mean ± SEM (standard deviation of the mean), n = 5/group (one experiment
representative of two). p<0.05, p<0.01.
(JPG)
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